Table S3.
Subgroup analyses of change from baseline to last visit in ACQ score of between-treatment differences with Cic 640 μg/day and Cic 160 μg/day (ITT)
| Variable | Cic 160 μg/day (N=120); n |
Cic 640 μg/day (N=125); n |
Change in ACQ score; Cic 640 μg/day vs Cic 160 μg/day
|
||
|---|---|---|---|---|---|
| LS mean (SE) | 95% CI | Two-sided P-value |
|||
| ACQ score at baseline | |||||
| ≤Median | 59 | 61 | −0.140 (0.1670) | −0.469, 0.188 | 0.4019 |
| >Median | 61 | 61 | −0.097 (0.1670) | −0.426, 0.231 | 0.5597 |
| Pre-study ICS dose, μg/day FP equivalent | |||||
| Low ≤250 | 43 | 42 | −0.291 (0.1985) | −0.681, 0.100 | 0.1437 |
| Medium >250–≤500 | 72 | 69 | −0.083 (0.1536) | −0.385, 0.219 | 0.5887 |
| High >500 | 5 | 11 | 0.567 (0.4923) | −0.402, 1.535 | 0.2506 |
| BMI, kg/m2 | |||||
| ≤30 | 84 | 89 | −0.045 (0.1383) | −0.318, 0.227 | 0.7429 |
| >30 | 36 | 33 | −0.275 (0.2209) | −0.710, 0.159 | 0.2135 |
| Smoking status | |||||
| Never | 109 | 106 | −0.109 (0.1253) | −0.355, 0.138 | 0.3868 |
| Current/former | 11 | 16 | −0.268 (0.3575) | −0.971, 0.435 | 0.4546 |
| Completion status | |||||
| Completer | 89 | 97 | −0.180 (0.1222) | −0.420, 0.061 | 0.1427 |
| Withdrawals | 31 | 25 | 0.253 (0.2245) | −0.188, 0.695 | 0.2602 |
| Baseline FEV1* | |||||
| ≤Median | 66 | 52 | −0.123 (0.1730) | −0.464, 0.217 | 0.4769 |
| >Median | 53 | 62 | −0.076 (0.1713) | −0.413, 0.261 | 0.6565 |
Notes:
*
Post hoc analysis. LS mean values are from ANCOVA.
Abbreviations: ACQ, Asthma Control Questionnaire; ANCOVA, analysis of covariance; BMI, body mass index; CI, confidence interval; Cic, ciclesonide; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate; ICS, inhaled corticosteroid; ITT, intention-to-treat; LS, least squares; SE, standard error.